JP2014502957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502957A5 JP2014502957A5 JP2013535097A JP2013535097A JP2014502957A5 JP 2014502957 A5 JP2014502957 A5 JP 2014502957A5 JP 2013535097 A JP2013535097 A JP 2013535097A JP 2013535097 A JP2013535097 A JP 2013535097A JP 2014502957 A5 JP2014502957 A5 JP 2014502957A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- inhibitor
- auristatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40576710P | 2010-10-22 | 2010-10-22 | |
| US61/405,767 | 2010-10-22 | ||
| US201161445785P | 2011-02-23 | 2011-02-23 | |
| US61/445,785 | 2011-02-23 | ||
| PCT/US2011/057130 WO2012054748A2 (en) | 2010-10-22 | 2011-10-20 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016252182A Division JP6467400B2 (ja) | 2010-10-22 | 2016-12-27 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴ ｍＴＯＲ経路インヒビターの間の相乗効果 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502957A JP2014502957A (ja) | 2014-02-06 |
| JP2014502957A5 true JP2014502957A5 (https=) | 2014-12-04 |
| JP6121906B2 JP6121906B2 (ja) | 2017-04-26 |
Family
ID=45975893
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535097A Active JP6121906B2 (ja) | 2010-10-22 | 2011-10-20 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果 |
| JP2016252182A Active JP6467400B2 (ja) | 2010-10-22 | 2016-12-27 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴ ｍＴＯＲ経路インヒビターの間の相乗効果 |
| JP2019003384A Pending JP2019070021A (ja) | 2010-10-22 | 2019-01-11 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴ ｍＴＯＲ経路インヒビターの間の相乗効果 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016252182A Active JP6467400B2 (ja) | 2010-10-22 | 2016-12-27 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴ ｍＴＯＲ経路インヒビターの間の相乗効果 |
| JP2019003384A Pending JP2019070021A (ja) | 2010-10-22 | 2019-01-11 | アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴ ｍＴＯＲ経路インヒビターの間の相乗効果 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9272052B2 (https=) |
| EP (2) | EP3581206B8 (https=) |
| JP (3) | JP6121906B2 (https=) |
| CN (2) | CN106563128B (https=) |
| AU (1) | AU2011316917B2 (https=) |
| CA (1) | CA2815363C (https=) |
| ES (2) | ES3004351T3 (https=) |
| TW (1) | TWI545134B (https=) |
| WO (1) | WO2012054748A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581206B8 (en) | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10983109B2 (en) | 2012-05-01 | 2021-04-20 | The Children's Hospital Of Philadelphia | Compositions and methods for treating B-lymphoid malignancies |
| WO2013173337A2 (en) * | 2012-05-15 | 2013-11-21 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014058947A1 (en) * | 2012-10-12 | 2014-04-17 | Sanofi | Compositions and methods for treating cancer using pi3k inhibitor and anti-cd19 maytansinoid immunoconjugate |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| JP6282745B2 (ja) | 2013-09-12 | 2018-02-21 | ハロザイム インコーポレイテッド | 修飾抗上皮成長因子受容体抗体およびその使用法 |
| JP6636925B2 (ja) | 2013-12-17 | 2020-01-29 | ノバルティス アーゲー | 細胞障害性ペプチドおよびその抱合体 |
| JP2017512814A (ja) * | 2014-04-07 | 2017-05-25 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤 |
| WO2015157297A1 (en) * | 2014-04-08 | 2015-10-15 | Seattle Genetics, Inc. | Optimal dosing of a cd19-antibody drug conjugate |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| HRP20190888T8 (hr) * | 2014-04-25 | 2019-10-04 | Pierre Fabre Médicament | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma |
| HUE047952T2 (hu) * | 2014-04-25 | 2020-05-28 | Pf Medicament | Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra |
| CA2951368A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| AU2015329625B2 (en) * | 2014-10-10 | 2018-04-05 | Pfizer Inc. | Synergistic auristatin combinations |
| US10435435B2 (en) * | 2015-07-24 | 2019-10-08 | The Arizona Board Of Regents On Behalf Of Arizona State University | Quinstatin compounds |
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| MA45862A (fr) * | 2016-08-04 | 2021-05-05 | Millennium Pharm Inc | Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30 |
| TWI851531B (zh) | 2016-08-09 | 2024-08-11 | 美商思進公司 | 具有改善之生理化學性質之具自我穩定連接子之藥物結合物 |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US11434303B2 (en) | 2017-06-28 | 2022-09-06 | Bluefin Biomedicine, Inc. | Anti-LY6H antibodies and antibody drug conjugates |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019088176A1 (ja) * | 2017-10-31 | 2019-05-09 | 国立大学法人神戸大学 | 抗体薬物複合体効果増強剤 |
| WO2019119822A1 (en) * | 2017-12-23 | 2019-06-27 | Uwell Biopharma Inc. | Pharmaceutical chimeric receptor composition and method thereof |
| TW202003047A (zh) * | 2018-03-23 | 2020-01-16 | 美商西雅圖遺傳學公司 | 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途 |
| JP2020019723A (ja) * | 2018-07-30 | 2020-02-06 | 国立大学法人 鹿児島大学 | 抗ＣＤ７０抗体とＩｇＧ結合ペプチドの複合体 |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2021178253A1 (en) * | 2020-03-03 | 2021-09-10 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
| WO2022122889A1 (en) * | 2020-12-10 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for detecting the activation of mtor pathway |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| BR112023018676A2 (pt) * | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| JP2025541340A (ja) | 2022-12-16 | 2025-12-18 | フィアン セラピューティクス エルティーディー | Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US20080051419A1 (en) * | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| ES2704199T3 (es) * | 2007-02-16 | 2019-03-14 | Vergell Medical S A | Profármacos de doble acción |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| EA020696B1 (ru) * | 2007-10-12 | 2015-01-30 | Сиэтл Дженетикс, Инк. | Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| CA2727278A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| WO2010081004A1 (en) * | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
| EP3581206B8 (en) | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
-
2011
- 2011-10-20 EP EP19173675.0A patent/EP3581206B8/en active Active
- 2011-10-20 AU AU2011316917A patent/AU2011316917B2/en active Active
- 2011-10-20 CN CN201610826795.0A patent/CN106563128B/zh active Active
- 2011-10-20 US US13/879,012 patent/US9272052B2/en active Active
- 2011-10-20 JP JP2013535097A patent/JP6121906B2/ja active Active
- 2011-10-20 CN CN201180051054.5A patent/CN103561759B/zh active Active
- 2011-10-20 ES ES19173675T patent/ES3004351T3/es active Active
- 2011-10-20 EP EP11835158.4A patent/EP2629801B3/en active Active
- 2011-10-20 CA CA2815363A patent/CA2815363C/en active Active
- 2011-10-20 TW TW100138137A patent/TWI545134B/zh active
- 2011-10-20 WO PCT/US2011/057130 patent/WO2012054748A2/en not_active Ceased
- 2011-10-20 ES ES11835158T patent/ES2730941T7/es active Active
-
2016
- 2016-01-27 US US15/008,365 patent/US10201615B2/en active Active
- 2016-12-27 JP JP2016252182A patent/JP6467400B2/ja active Active
-
2018
- 2018-12-19 US US16/226,509 patent/US11607460B2/en active Active
-
2019
- 2019-01-11 JP JP2019003384A patent/JP2019070021A/ja active Pending
-
2023
- 2023-02-09 US US18/166,491 patent/US12496353B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502957A5 (https=) | ||
| AU2016202621B2 (en) | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer | |
| Li et al. | The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively | |
| JP2009501800A5 (https=) | ||
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| JP2021509009A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2020525542A5 (https=) | ||
| JP2020505433A5 (https=) | ||
| JP2008530142A5 (https=) | ||
| JP2017515802A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2016503023A5 (https=) | ||
| JP2020517652A5 (https=) | ||
| JP2012512158A5 (https=) | ||
| JP2014532648A5 (https=) | ||
| August et al. | Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions | |
| KR20240082379A (ko) | 암 치료 방법 및 이의 약제학적 조성물 | |
| Davidkova et al. | Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome | |
| Cheson | Targeted treatment and new agents in follicular lymphoma | |
| Sacknovitz et al. | Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials | |
| WO2025021587A1 (en) | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof | |
| Taft et al. | On 01910. Na | |
| WO2021188871A1 (en) | Small molecule inhibitors of interleukin-4 | |
| Gutierrez Tordera | Targeting acute myeloid leukemia stem cell: current status and clinical application |